Cryoport Reports Strong Q3 Results, Raises FY25 Outlook
Cryoport reported Q3 revenue of $44.2 million, exceeding estimates. Loss per share of 18 cents beat expectations of 21 cents. Commercial Cell and Gene Therapy revenue increased by 36%. Cryoport raised 2025 revenue guidance to $170-$174 million. The company repurchased 483,397 shares, showing confidence in stock.
View signal analysis